---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-056889"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T11:49:55.349361+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma reports record Q1 revs $106.8M (+65.6% YoY), raises FY2023 guidance across all metrics

## Summary
- Record net revenue of $106.8M, up 65.6% YoY; GAAP net income $1.0M, diluted EPS $0.06.
- Adjusted non-GAAP EBITDA $33.0M (vs $4.3M Q1 2022); adj. diluted EPS $1.17 (vs -$0.12).
- Cortrophin Gel net sales $16.3M (Q1 2022: $1.3M); FY guidance maintained at $80-90M.
- Raised FY2023 guidance: rev $385-410M (from $360-385M), adj. EBITDA $97-107M, adj. EPS $2.99-3.45.
- Generics revenue $63.7M (+29.7% YoY); established brands/other $26.7M (+90.0%). FDA inspection with zero 483s.

## SEC filing metadata
- accession: 0001104659-23-056889
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000110465923056889/0001104659-23-056889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000110465923056889/tm2314831d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-056889
- JSON: https://secwatch.observer/filing/0001104659-23-056889.json
- Plain text: https://secwatch.observer/filing/0001104659-23-056889.txt

## Key facts
- Earnings Releases
  ANI PHARMACEUTICALS INC reported full-year 2023 results: revenue $385 million to $410 million, EPS $2.99 to $3.45. Guidance raised.
  - Period: full-year 2023
  - Revenue: $385 million to $410 million
  - EPS: $2.99 to $3.45
  - Guidance: raised
  - Result: guidance update
  source text: Full Year 2023 Guidance -- Raises Company net revenue guidance to $385 million to $410 million from $360 million to $385 million; adjusted non-GAAP EBITDA guidance to $97 million to $107 million from $78 million to $88 million; adjusted non-GAAP earnings per share to $2.99 to $3.45 from $2.09 to $2.59
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000110465923056889/0001104659-23-056889-index.htm
- Earnings Releases
  ANI PHARMACEUTICALS INC reported quarter ended March 31, 2023 results: revenue $106.8 million, net income $1.0 million, EPS $0.06.
  - Period: quarter ended March 31, 2023
  - Revenue: $106.8 million
  - Net income: $1.0 million
  - EPS: $0.06
  - Result: reported results
  source text: First Quarter 2023 Financial Results -- Record quarterly net revenues of $106.8 million, representing year-over-year growth of 65.6%; 2023 first-quarter net income available to common shareholders of $1.0 million and diluted GAAP income per share of $0.06
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000110465923056889/0001104659-23-056889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.